| Literature DB >> 30316994 |
Cristina Belizna1, Francesca Pregnolato2, Sebastien Abad3, Jaume Alijotas-Reig4, Howard Amital5, Zahir Amoura6, Laura Andreoli7, Emmanuel Andres8, Achile Aouba9, Sule Apras Bilgen10, Laurent Arnaud11, Boris Bienvenu12, Viktoria Bitsadze13, Patrick Blanco14, Miri Blank5, Maria Orietta Borghi2, Antonia Caligaro15, Elisabeta Candrea16, Valentina Canti17, Laurent Chiche18, Jean Marie Chretien19, Jan Willem Cohen Tervaert20, Laura Damian21, Teresa Delross15, Emmanuelle Dernis22, Katrien Devreese23, Aleksandra Djokovic24, Enrique Esteve-Valverde25, Maria Favaro15, Céline Fassot26, Raquel Ferrer-Oliveras27, Alban Godon28, Mohamed Hamidou29, Milena Hasan30, Daniel Henrion26, Bernard Imbert31, Pierre Yves Jeandel32, Pascale Jeannin28, Patrick Jego33, Noemie Jourde-Chiche34, Jamilya Khizroeva13, Olivier Lambotte35, Cédric Landron36, Jose Omar Latino37, Estibaliz Lazaro38, Karina de Leeuw39, Thomas Le Gallou33, Levent Kiliç10, Maarten Limper40, Laurent Loufrani26, Romain Lubin26, Nadine Magy-Bertrand41, Guillaume Mahe42, Alexander Makatsariya13, Thierry Martin43, Christian Muchardt44, Gyorgy Nagy45, Loukman Omarjee42, Pieter Van Paasen46, Gilles Pernod47, Florence Perrinet48, Gilberto Pïres Rosa49, Marc Antoine Pistorius50, Amelia Ruffatti15, Fatma Said51, Patrick Saulnier19, Damien Sene52, Loic Sentilhes53, Ova Shovman5, Jean Sibilia11, Crina Sinescu54, Natasa Stanisavljevic24, Ljudmila Stojanovich24, Lai Shan Tam55, Angela Tincani7, Fréderic Tollis56, Sebastian Udry37, Marie Noelle Ungeheuer57, Mathilde Versini58, Ricard Cervera59, Pier Luigi Meroni2.
Abstract
The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4-16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.Entities:
Keywords: Antiphospholipid syndrome; Hydroxychloroquine; Primary antiphospholipid syndrome; Secondary prevention
Mesh：
Substances：
Year: 2018 PMID： 30316994 DOI： 10.1016/j.autrev.2018.05.012
Source DB: PubMed Journal: Autoimmun Rev ISSN： 1568-9972 Impact factor: 9.754